Editor of Patient Care Online.
Topical Steroid Withdrawal: Study Identifies Mitochondrial Dysfunction as a Potential Target for Treatment
NIH researchers also proposed new diagnostic criteria that include a combination of major and minor symptoms, offering improved sensitivity for identifying TSW cases.
FDA Greenlights First Rivaroxaban Generics (2.5 mg): Daily Dose
Your daily dose of the clinical news you may have missed.
Early Responsive Parenting Intervention Shows Modest, Short-Term Impact on Childhood Obesity
New data shows that early-life responsive parenting can lower childhood BMI, but effects diminished by age 9, highlighting the need for ongoing obesity prevention efforts.
Emergence of Trichophyton Indotineae: A Call for Culture-Driven Antifungal Therapy
Elizabeth Swanson, MD, shares how the rise of T.indotineae, a terbinafine-resistant fungal species, has shifted her treatment approach.
Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose
Rethinking Shingles in Children: Expert Insights for Primary Care
Shingles is increasingly being observed in healthy, immunocompetent children. Elizabeth Swanson, MD, discusses how to recognize and respond.
Measles Resurgence and Vaccine Efficacy: A Conversation with Elizabeth Swanson, MD
Dr Swanson discusses the resurgence of measles and emphasizes the safety and efficacy of the measles vaccine.
Bionic Pancreas for Type 1 Diabetes Found Feasible to Implement in Primary Care
The iLet bionic pancreas system conferred an average glucose of less than 183 mg/dL in 97% of adults with T1D in a small study.
Dupilumab Cuts Food Allergy IgE Levels in Small Study: Daily Dose
Hand, Foot, and Mouth Disease Update: A Conversation with Elizabeth Swanson, MD
Elizabeth Swanson, MD, discusses the changing face of HFMD, focusing on the increasingly prevalent coxsackievirus A6 strain and its unique characteristics
JiaDe Yu, MD: When to Refer Pediatric Patients with Suspected Contact Dermatitis
In an interview at AAD 2025, Dr Yu emphasized the importance of managing contact dermatitis early and effectively to prevent long-term complications.
Dermatology Therapeutics: Updates for Primary Care from AAD 2025
Research included new findings on topical and systemic treatments for atopic dermatitis, psoriasis, alopecia areata, and other chronic skin disorders.
FDA Approves Neffy 1 mg Epinephrine Nasal Spray: Daily Dose
Study: COVID-19 Pandemic Disruptions in Cancer Screening Show Uneven Recovery in 2023
Cervical cancer screening rates remained below prepandemic levels, while rates for breast and colorectal cancers rebounded from pandemic declines.
Women as Young as Age 30 May Experience Perimenopause Symptoms: Daily Dose
Contact Dermatitis: Expert Insights on First-Line and Emerging Therapies
JiaDe 'Jeff' Yu, MD, discusses first-line therapies, emerging biologics, and the potential of molecular biomarkers for improved diagnosis.
Advances in Dermatology Therapeutics: Key Insights from AAD 2025
Highlights include new data on roflumilast cream 0.15%, an investigational anti-OX40 ligand monoclonal antibody, and more.
JiaDe Yu, MD: Key Signs of Allergic Contact Dermatitis in Children
AAD 2025. JiaDe Yu, MD, discusses key clinical signs of pediatric ACD, when to consider patch testing, and how identifying contact allergens can improve patient care.
Elizabeth Swanson, MD: When HSV Causes Big Dermatologic Problems
Elizabeth Swanson, MD, breaks down the role of the Herpes Simplex Virus in 3 special circumstances, part of her AAD 2025 presentation, "Big Rashes In Little Patients."
Recognizing Allergic Contact Dermatitis in Children: Expert Pearls at AAD 2025
JiaDe Yu, MD, shares key takeaways from his presentation on pediatric allergic contact dermatitis.
The Complexities of Treating Rosacea, with Benjamin Ungar, MD
Benjamin Ungar, MD, explains the phenotypic and molecular manifestations of Rosacea, and the work still needed to develop targeted treatments.
Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast
“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.
Atopic Dermatitis Breakthrough: Linda Stein Gold, MD, on Tapinarof's Treatment-Free Benefits
AAD 2025. Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial.
Benjmain Ungar, MD: Addressing the Immunological Causes of Seborrheic Dermatitis
Benjamin Ungar, MD, discusses his presentation at AAD 2025 covering advances and updates about rosacea and seborrheic dermatitis.
Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation
AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.
Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis
AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.
Bimekizumab Demonstrates Sustained Efficacy in Moderate-to-Severe Plaque Psoriasis Over Five Years
AAD 2025. New research indicates that dual inhibition of IL-17A and IL-17F with bimekizumab maintains high rates of complete skin clearance for up to 5 years.
Patient Benefit Index Complements Traditional Psoriasis Outcome Measures, Study Finds
Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.
Depemokimab Shows Significant Improvements in Rhinosinusitis with Nasal Polyps: New Research
AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.
Study Reveals Persistent Telehealth Disparities in Depression Management: Daily Dose
